Hepatitis B Virus Surface Antigen (HBsAg)-Positive and HBsAg-Negative Hepatitis B Virus Infection among Mother-Teenager Pairs 13 Years after Neonatal Hepatitis B Virus Vaccination

Qing-Qing Yao, Xiao-Lian Dong, Xue-Cai Wang, Sheng-Xiang Ge, An-Qun Hu, Hai-Yan Liu, Yueping Alex Wang, Quan Yuan, Ying-Jie Zheng

Department of Epidemiology, School of Public Health, the Key Laboratory on Public Health Safety, Ministry of Education, Fudan University, Shanghai, China; Center for Disease Control and Prevention of Deqing County, Huzhou, Zhejiang Province, China; National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian Province, China; Anqing City Hospital, Anqing, Anhui Province, China; Perinatal & Reproductive Epidemiology Research Unit, School of Women’s and Children’s Health, the University of New South Wales, Sydney, Australia

It is unclear whether a mother who is negative for hepatitis B virus surface antigen (HBsAg) but positive for hepatitis B virus (HBV) is at potential risk for mother-to-child transmission of HBV. This study, using a paired mother-teenage population, aimed to assess whether maternal HBsAg-negative HBV infection (hnHBI) is a significant source of child HBV infection (HBI). A follow-up study with blood collection has been conducted on the 93 mother-teenager pairs from the initial 135 pregnant women-newborn pairs 13 years after neonatal HBV vaccination. Serological and viral markers of HBV have been tested, and phylogenetic analysis of HBV isolates has been done. The HBI prevalence was 1.9% (1 hnHBI/53) for vaccinees aged 1 to 13 years in comparison with 7.0% (1 HBI/14) for those without HBI mothers (4). Similar viral sequences have been found in one pair of whom both the mother and teenager have had HBV. It is unclear whether a mother who is negative for hepatitis B virus surface antigen (HBsAg) but positive for hepatitis B virus (HBV) accounts for a significant portion of morbidity and mortality worldwide (1). With the introduction of a safe and effective HBV vaccination for neonates, the prevalence of chronic carriers who are identified as being hepatitis B virus surface antigen (HBsAg) positive has markedly dropped to 1% to ~2% among the vaccinees (2, 3).

The HBV vaccination protocols for neonates vary according to their mothers’ HBsAg statuses (3). Since it has been established that the combined three 10-μg-dose HBV vaccines plus hepatitis B immune globulin (HBIG) would provide better protection than the three 5-μg- or 10-μg-dose HBV vaccines alone (4), the Chinese government introduced a compulsory neonatal HBV vaccination program in 1992 (2): for babies born to HBsAg-positive mothers, three 10-μg-dose HBV vaccines plus a dose of 200 IU HBIG are to be provided, whereas for those born to HBsAg-negative mothers, only three 5-μg-dose vaccines are to be used.

Determining HBsAg status has been routinely undertaken for the mothers during a prenatal visit or before delivery through serological methods, which target the major “a” determinant of HBsAg. However, current available commercial assays could not recognize the following scenarios: the early-window period of acute HBV infection (HBI), occult hepatitis B virus infection (OBI) (defined as the presence of HBV DNA in the liver [with or without detectable HBV DNA in the serum]) combined with a false OBI test result due to the presence of a modified HBsAg (caused by the “a” determinant mutations) (7–10). In current practice, differentiation among the scenarios noted above is unlikely unless follow-up studies are performed. Therefore, nearly all serology-based studies have treated such HBsAg-negative HBsAg (anti-HBs) (24–26). Recent publications reported that the prevalence of hnHBI was much higher among the vaccinees or even those with high-level antibodies against HBsAg (anti-HBs) (24–26). Among teenagers who had a lower level of HBV load and a higher proportion of genotype-C strains, which were accompanied by differentiated mutations (Q129R, K141E, and Y161N) of the “a” determinant of the HBV surface gene. Our findings suggest that mother-to-teenager transmission of hnHBI can occur among those in the neonatal HBV vaccination program.
history of HBI but who no longer tested positive for HBsAg, only 24% responded to HBV vaccines marked by positive anti-HBs (28). Therefore, it would be hypothesized that HBI in the vaccinees may have originated mainly from their mothers.

In this study, we used a paired mother-teenager population to ascertain whether maternal HBI is a significant source of HBI for the child by analyzing the occurrence of HBI, determining the phylogenetic relationship between concurrent isolates, and assessing the risk of child HBI attributable to maternal HBI.

**MATERIALS AND METHODS**

**Participants.** From 7 October 1996 to 17 May 1997, 135 pregnant women-newborn pairs were enrolled in a follow-up vaccination program in Deqing County, Zhejiang Province, China (29). Of the 135 pregnant women, 100 were categorized as non-HBI and 35 had HBI; further, 16 of the 35 with HBI were also HBV e antigen positive. At 0, 1, and 6 months after birth, the newborns received HBV vaccinations, with each administered a 5-μg dose of yeast-derived recombinant hepatitis B vaccine (Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, China). All HBV indexes were determined by using radioimmunoassay-based commercial kits (Shanghai Kehua Bio-engineering Co., Ltd., Shanghai, China) (29).

**Follow-up and data collection.** From July to August 2010, a repeat study was conducted on the 135 initial pregnant woman-newborn pairs, who were now mother-teenager pairs. Informed consent was obtained from the teenagers’ parents or participating mothers prior to specimen collection. Demographic data on the teenagers and mothers were obtained by using a structured questionnaire, and 5-ml blood samples were collected. Data on the administration of HBV booster vaccines for the teenagers were obtained from their vaccination records at the Center for Disease Prevention and Control, Deqing County, Zhejiang Province, China.

**Serological and virological testing.** All serum specimens were divided into aliquots in two separate sterile tubes. The first tube of serum was used for the alanine aminotransferase (ALT) assay by using commercial kits based on the method of analysis of lactate dehydrogenase by UV radiation (Shanghai Kehua Bio-engineering Co., Ltd., Shanghai, China); the second tube was used for the detection of HBsAg, anti-HBs, and antibodies against hepatitis B virus core antigen (anti-HBc) by using commercial kits for an electrochemiluminescence immunoassay (Elecsys; Roche Diagnostics, Inc.). To avoid potential false-negative results caused by a single test, the HBsAg was further tested by enzyme-linked immunosorbent assay (ELISA)-based HBsAg kits (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Beijing, China).

Viral DNA extractions from 100 μl of serum were performed in parallel for both the first and second tube. The levels of HBV DNA load were...
TABLE 1 Features of the teenagers and the mothers by the mothers’ HBI statuses

<table>
<thead>
<tr>
<th>Feature</th>
<th>HBI mothers (n = 40)</th>
<th>Non-HBI mothers (n = 53)</th>
<th>P value&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mothers&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Education: junior middle school or above</td>
<td>31 (77.5)</td>
<td>39 (73.5)</td>
<td>0.66</td>
</tr>
<tr>
<td>Occupation: peasant</td>
<td>22 (55.0)</td>
<td>28 (52.8)</td>
<td>0.50</td>
</tr>
<tr>
<td>Annual family income ≥ 50,000 yuan</td>
<td>26 (65.0)</td>
<td>32 (60.4)</td>
<td>0.65</td>
</tr>
<tr>
<td>ALT ≥ 40 U/liter</td>
<td>2 (5.0)</td>
<td>6 (11.3)</td>
<td>0.46*</td>
</tr>
<tr>
<td>anti-HBc positive</td>
<td>32 (80.0)</td>
<td>41 (77.4)</td>
<td>0.76</td>
</tr>
<tr>
<td>anti-HBs positive</td>
<td>8 (20.0)</td>
<td>30 (56.0)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Teenagers&lt;sup&gt;d&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex (male)</td>
<td>22 (55.0)</td>
<td>31 (58.5)</td>
<td>0.74</td>
</tr>
<tr>
<td>Vaginal delivery: yes</td>
<td>34 (85.0)</td>
<td>40 (75.5)</td>
<td>0.26</td>
</tr>
<tr>
<td>Full-term delivery: yes</td>
<td>40 (100.0)</td>
<td>51 (96.2)</td>
<td>0.89</td>
</tr>
<tr>
<td>Only breastfeeding up to 6 months: yes</td>
<td>32 (80.0)</td>
<td>43 (81.1)</td>
<td>0.69</td>
</tr>
<tr>
<td>Normal infantile growth and development: yes</td>
<td>33 (82.5)</td>
<td>42 (79.2)</td>
<td>0.74</td>
</tr>
<tr>
<td>Passive smoking: yes</td>
<td>22 (55.0)</td>
<td>34 (64.2)</td>
<td>0.33</td>
</tr>
<tr>
<td>Dental treatment: yes</td>
<td>18 (45.0)</td>
<td>23 (43.4)</td>
<td>0.88</td>
</tr>
<tr>
<td>History of diseases: yes</td>
<td>4 (10.0)</td>
<td>2 (3.8)</td>
<td>0.40*</td>
</tr>
<tr>
<td>History of injury: yes</td>
<td>36 (90.0)</td>
<td>49 (92.5)</td>
<td>0.72*</td>
</tr>
<tr>
<td>Sharing of toothbrush: yes</td>
<td>3 (7.5)</td>
<td>1 (1.9)</td>
<td>0.31*</td>
</tr>
<tr>
<td>Transfusion history: yes</td>
<td>2 (5.0)</td>
<td>0 (0.0)</td>
<td>0.18*</td>
</tr>
<tr>
<td>History of surgical operation: yes</td>
<td>4 (10.0)</td>
<td>1 (1.9)</td>
<td>0.16*</td>
</tr>
<tr>
<td>Initial HBV vaccine response: yes</td>
<td>34 (85.0)</td>
<td>46 (86.8)</td>
<td>0.81</td>
</tr>
<tr>
<td>History of booster: yes</td>
<td>34 (85.0)</td>
<td>41 (77.4)</td>
<td>0.36</td>
</tr>
<tr>
<td>ALT ≥ 40 U/liter</td>
<td>1 (2.5)</td>
<td>4 (7.5)</td>
<td>0.46</td>
</tr>
</tbody>
</table>

<sup>a</sup> HBI, hepatitis B virus infection; Prop, proportion; ALT, alanine aminotransferase; anti-HBs, antibody to hepatitis B virus surface antigen; anti-HBc, antibody to hepatitis B virus core antigen.

<sup>b</sup> *, Fisher’s exact test.

<sup>c</sup> Age in years (mean ± standard deviation), 38.5 ± 2.4 (HBI mothers) or 39.9 ± 3.9 (non-HBI mothers) (P = 0.04).

<sup>d</sup> Age in years (mean ± standard deviation), 13.7 ± 0.1 (HBI mothers) or 13.7 ± 0.1 (non-HBI mothers) (P = 0.72); birth weight in kilograms (mean ± standard deviation), 3.26 ± 0.40 (HBI mothers) or 3.35 ± 0.37 (non-HBI mothers) (P = 0.26).

measured by using Premix Ex Taq (Perfect Real Time) kits from TaKaRa Biotechnology (Dalian) Co. Ltd., Dalian, China, and primer sets, described elsewhere (21). Positive results in both tubes indicated a positive HBV load. All tests were performed strictly according to the manufacturer’s instructions.

**Nest PCR for HBV surface gene, sequencing, and phylogenetic analysis.** The second tube of serum (200 μl) was also used for performing a nested PCR with the HBV surface gene (21). The DNA extraction was performed using QIAamp DNA blood minikits (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Briefly, a 544-nucleotide (nt) segment of the HBV surface gene, nt 223 to 766 relative to the HBV prototype (GenBank accession no. AB033557), was amplified using primers S1 (5'-CCTGCTGTGCTGCTCATGTC-3') and S2 (5'-ATACCAAAAGAAAAAAGAAA-3') for the first round of PCR and primers S3 (5'-GGGCTTTTCTTGTGTCAG-3') and S4 (5'-GGGACTCAGATGTTGACTG-3') for the second round. The PCR cycling conditions for both rounds consisted of denaturing for 40 s at 94°C, annealing for 40 s at 55°C, and extension for 40 s at 72°C, with 35 and 25 cycles used for the first and second rounds, respectively.

The PCR products for the HBV surface gene were purified and further sequenced on an ABI Prism 3100X automatic genetic analyzer (Applied Biosystems Life Technologies Corporation). The viral sequences were aligned using Lasergene (version 7.10; DNASTAR Inc.). Genetic distances between pairs of virus isolates were calculated using the Tamura-Nei method. A phylogenetic tree was constructed using the maximum-likelihood method and evaluated using the bootstrap test with 500 replications in MEGA software (version 5.05; available at http://www.megasoftware.net/). Prototype HBV strains of all genotypes (A to I) were used as references in the analysis; their GenBank accession numbers are as follows: genotype A, AY373432 and DQ315784; genotype B, BX97850, AY003901, AY1206390, and AY206391; genotype C, AB112063 and AB033557; genotype D, EU939680 and X65259; genotype E, AB302431 and AB091256; genotype F, AB056905 and AB116654; genotype G, AB056515 and AB064313; genotype H, AB056661 and AB375161; and genotype I, AF241048 and AF241490. The serotypes of all identified HBV strains were determined by their amino acid sequences as previously reported (30).

A positive HBV DNA result was defined as being positive for either HBV load or the HBV surface gene for the HBVAg-positive participant or being positive for both HBV load and the HBV surface gene for the HBVAg-negative participant. Current HBI (in 2010) was defined as being either <sub>hn</sub>HBI or <sub>hp</sub>HBI. Prenatal HBI (in 1996 or 1997) was defined as being HBVAg positive only.

For teenagers without current HBI, a protective immunity to HBV was defined as an anti-HBs level ≥ 10.0 IU/liter (22). Initial vaccine response was defined as an anti-HBs level ≥ 10.0 IU/liter for the infants at 7 or 12 months.

**TABLE 2 Relationship of HBI statuses among the 93 mother-teenager pairs**

<table>
<thead>
<tr>
<th>Group</th>
<th>Mother’s HBI status (total no.)</th>
<th>HBI&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Anti-HBs&lt;sup&gt;+&lt;/sup&gt;</th>
<th>Anti-HBs&lt;sup&gt;−&lt;/sup&gt;</th>
<th>No. (%) of anti-HBs&lt;sup&gt;c&lt;/sup&gt; teenagers</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>HBI (40)</td>
<td>2 (5.0)</td>
<td>26 (65.0)</td>
<td>12 (30.0)</td>
<td>4 (10.0)</td>
</tr>
<tr>
<td>2</td>
<td>&lt;sub&gt;hn&lt;/sub&gt;HBI, HBV DNA&lt;sup&gt;+&lt;/sup&gt; (6)</td>
<td>1* (16.7)</td>
<td>2 (33.3)</td>
<td>3 (50.0)</td>
<td>0 (0.00)</td>
</tr>
<tr>
<td>3</td>
<td>&lt;sub&gt;hp&lt;/sub&gt;HBI, HBV DNA&lt;sup&gt;−&lt;/sup&gt; (25)</td>
<td>1* (4.0)</td>
<td>18 (72.0)</td>
<td>6 (24.0)</td>
<td>4 (16.0)</td>
</tr>
<tr>
<td>4</td>
<td>&lt;sub&gt;hn&lt;/sub&gt;HBI, HBV DNA&lt;sup&gt;−&lt;/sup&gt; (9)</td>
<td>0 (0.0)</td>
<td>6 (66.7)</td>
<td>3 (33.3)</td>
<td>0 (0.00)</td>
</tr>
<tr>
<td>5</td>
<td>Non-HBI (53)</td>
<td>1* (1.9)</td>
<td>30 (56.6)</td>
<td>22 (41.5)</td>
<td>0 (0.00)</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>3 (3.2)</td>
<td>56 (60.2)</td>
<td>34 (36.6)</td>
<td>4 (4.3)</td>
</tr>
</tbody>
</table>

<sup>a</sup> HBI, hepatitis B virus infection; HBV, hepatitis B virus; anti-HBs, antibody to hepatitis B virus surface antigen; anti-HBc, antibody to hepatitis B virus core antigen.

<sup>b</sup> P, Fisher’s exact test.

<sup>c</sup> Anti-HBs<sup>+</sup>, antibody to hepatitis B virus surface antigen; anti-HBs<sup>−</sup>, antibody to hepatitis B virus core antigen. Statistical significance was determined by Fisher’s exact test. For teenagers’ HBI statuses, overall P = 0.46 for 1 and 3, P = 0.14 for 2 and 3 plus 4, and 5, P = 0.28 for 2, 3, 4, and 5, P = 0.63 for <sup>−</sup>HBI plus 3, 4, and 5, and P = 1.00 for <sup>−</sup>HBI plus 3 and 5 plus 4. For teenagers’ anti-HBs statuses, overall P = 0.04 for 1 and 3, P = 0.05 for 2, 3 plus 4, and 5, P = 0.02 for 2, 3, 4, and 5, P = 0.02 for <sup>−</sup>HBI plus 3, 4, and 5, and P = 0.02 for <sup>−</sup>HBI plus 3 and 5 plus 4.
The genotype-specific surface gene mutants of HBV in this study were compared with archived HBV strains (95 genotype B and 48 genotype C) that had been isolated from \( \mu \)HBI from the general population in the same county (31).

**Statistical analysis.** The means, medians, or proportions are presented as descriptive statistics. In the bivariate analyses, the Student’s \( t \) test, the Mann-Whitney test, and Pearson \( \chi^2 \) test or Fisher’s exact test were used to compare the means, medians, and proportions, respectively. All \( P \) values were 2 sided. The results were considered statistically significant when \( P < 0.05 \). All analyses were performed using SAS 8.02 for Windows (SAS Institute, Cary, NC).

Ethical approval was granted by the Human Subjects Committee Review Board of the School of Public Health, Fudan University.

**Nucleotide sequence accession numbers.** The GenBank accession numbers for the sequences of the 31 strains determined in this work are KC117267 to KC117297.

## RESULTS

**Characterization of the follow-up and HBI cases identified in the mother-teenager pairs.** There were 16 mother-teenager pairs who refused to participate, 17 pairs who could not be contacted, and 8 mothers and 1 teenager alone who refused to provide blood samples. The remaining 93 pairs (68.9%) who had completed the questionnaire data and provided blood samples were included for further analysis (Fig. 1). The follow-up rate, 77.1%, for the 35 HBsAg-positive pregnant women diagnosed in 1996 or 1997 was not significantly different from that of 66.0% (66/100) for HBsAg-negative pregnant women (\( \chi^2 = 1.05, P = 0.22 \)) (Fig. 1).

The HBI status of the 93 pairs described above was determined again in 2010 with the more sensitive assays, i.e., PCR, sequencing methods, and new HBsAg assays. Forty HBI mothers (34 \( \mu \)HBI and 6 \( \mu \)HBI) and 3 HBI teenagers (1 \( \mu \)HBI and 2 \( \mu \)HBI) were identified (Fig. 1). For the mothers, their HBI status exhibited a 75.3% concordance between the data determined in 1996 or 1997 and in 2010 (McNemar \( \chi^2 = 7.3, P = 0.01 \)); all the six \( \mu \)HBI mothers classified in 2010 were also HBsAg negative in 1996 or 1997 (Fig. 1).

**Feature comparison of the teenagers and the mothers by mothers’ HBI statuses.** In comparison with those of the non-HBI mothers, the ages of HBI mothers were slightly lower and the proportion of mothers who were anti-HBs positive was lower; however, the other features of the mothers (education level, occupation, annual family income, abnormal ALT level, and anti-HBc status) and of the teenagers (age, sex ratio, delivery and feeding methods, infant growth and development, history of diseases, dental treatment, injuries, surgical operation, transfusion, toothbrush sharing, passive smoking, initial response to and boost with HBV vaccine, and abnormal ALT level) were similar (Table 1).

**Relationship of HBI status among the 93 mother-teenager pairs.** For all teenagers, the prevalences of HBI (1 \( \mu \)HBI plus 2 \( \mu \)HBI), of being anti-HBs positive, and of being anti-HBc positive were 3.2%, 60.2%, and 4.3%, respectively (Table 2).

Four anti-HBc-positive cases were identified exclusively among teenagers whose mothers were \( \mu \)HBI in both 1996 or 1997 and 2010, together with a detectable HBV DNA in 2010 (Fig. 1), but only one of the teenagers developed \( \mu \)HBI. And the difference in the proportions of being anti-HBc positive was statistically significant in teenage children of mothers with different HBI status based on the results determined in 1996 or 1997 or in 2010 (Table 2, Fig. 1).

The proportions of HBI were 16.7% (1/6), 2.9% (1/34), and
1.9% (1/53), respectively, in teenage children of the mothers with hnHBI, hpHBI, and non-HBI. However, the difference in the proportions of HBI was not statistically significant in teenage children of mothers with different HBI statuses based on the results determined in 1996 or 1997 or in 2010 (Table 2, Fig. 1).

Viral and phylogenetic analysis of HBsAg-negative and HBsAg-positive HBV strains. Of the 93 mother-teenage pairs, 29 mothers and 2 teenagers were identified as being HBV DNA positive, with a median HBV DNA load of 3.47 × 10^{2} IU/ml. The hpHBI cases exhibited a slightly higher but statistically nonsignificant median HBV DNA load, 3.92 × 10^{2} IU/ml (23 cases; range, <5.0 IU/ml to >1.91 × 10^{3} IU/ml), compared with the level seen with hnHBI cases, 2.47 × 10^{2} IU/ml (8 cases; range, 4.33 × 10^{1} IU/ml to >6.25 × 10^{3} IU/ml).

A total of 31 HBV strains, 29 from mothers (6 from hpHBI and 23 from hnHBI) and 2 from teenagers (both from cases of hnHBI), were identified, and the overall ratio of genotype B to genotype C was 16/15 (Fig. 2). The proportion of genotype C was significantly higher for cases with hnHBI (7/8) than for those with hpHBI (8/23, P = 0.02, Fisher’s exact test). All genotype-B and genotype-C HBV strains identified in this study had the serotypes of adw and adr, respectively.

In comparison with the archived HBV strains that were isolated from individuals with hpHBI in the same region, the overall mutation rate per strain was consistent between the hpHBI strains in this study and archived hpHBI strains (7.04 per 1,000 and 7.19 per 1,000, respectively). In the hpHBI cases from this study, the observed mutations of the 100th, 120th, 126th, 156th, 158th, and 164th amino acid positions for genotype-B strains and those of the 120th and 141st amino acid positions for genotype-C strains were exactly the same as those archived. Neither the specific mutations listed above nor those with high frequencies, such as those at the 133rd and 161st positions, from the hpHBI cases were identified in the hnHBI cases in this study. The two alleles identified in the hpHBI cases in this study (Y161N and K141E) showed mutation profiles different from those archived (Y161F/S and K141G). In addition, the Q129R allele identified in two hpHBI cases (one teenager and one mother) was not observed in those archived.

There was one mother-teenager pair (MO-78 and TE-78) both with hpHBI and infected with HBV strains (Fig. 2). Further sequence analysis showed that the viruses from this mother and her child are closely related, with the only difference at the site of Q129R (Table 3).

**DISCUSSION**

Our results show that the mother and the teenager in one pair were both infected with hpHBI and that the virus sequences are highly similar, which suggests that mother-teenager transmission of hpHBI has occurred among 13-year-old teenagers who have received neonatal HBV vaccination. In this study, 3.2% of the 93 teenagers had been infected with either hpHBI or hnHBI even though all of them had received HBV vaccination since birth and 81% of them had received at least one booster dose before the age of 13 years. Further, this prevalence among teenage children of hpHBI mothers, 16.7% (1/6), was markedly higher than the prevalences among those of hnHBI and non-HBI mothers, 2.9% (1/34) and 1.9% (1/53), respectively; but the difference was not statistically significant. Thus, it remains inconclusive whether maternal hpHBI could play a major role in its transmission to her child.
The mechanism of transmission of \( \text{HBV} \) has been well understood. Early-life HBV infection from mother to child, which is mainly determined by the mother’s HBV DNA level, can occur during the prenatal (through the placenta), perinatal, or postnatal stages of life (32–34). Furthermore, natural and chronic-carrier infection of HBV can still occur over time, even for those who have received neonatal HBV vaccinations (22) or have been living in areas of high endemicity (35–37). Though \( \text{HBV} \) has been established in a variety of populations, including those with neonatal HBV vaccination (24–26), the source of this infection remains largely unknown. In this study, we did observe the transmission of a one mother’s \( \text{HBV} \) to her child (one case), which would imply a role of maternal \( \text{HBV} \) that is possibly similar to that of maternal \( \text{HBV} \). But other sources (father, siblings, friends, etc.) rather than the mother remain possible, as indicated by the ME-102 and TE-102 pair in this study.

In agreement with previous studies (21, 26), we found more genotype-C HBV strains and a lower viral load in \( \text{HBV} \) cases than in \( \text{HBV} \) cases. The site-specific amino acid analysis identified three mutations (Q129R, K141E, and Y161N) that were unique to \( \text{HBV} \) cases. The Q129R or K141E mutant, which has been suggested as a diagnostic-escape strain (9), had established its infectivity among the vaccinees. Interestingly, both \( \text{HBV} \) teenagers identified had received an extra booster dose of HBV vaccine in the past 13 years and had a detectable level of anti-HBs (Table 3).

Our findings raise the issue of whether maternal \( \text{HBV} \) can play a major role in its transmission to the child in the current HBV vaccination program. In comparison with the prevalence of \( \text{HBV} \) among the pregnant women (approximately 3% to 4% [L. N. Tao, personal communication]) and in the general population (7.2%) (2), the prevalence of \( \text{HBV} \) among the pregnant women is not statistically insignificant or is even higher (38), as indicated also by our results showing that the \( \text{HBV} \) prevalence was 10.2% (6/59) among the tested mothers. And the inability to routinely identify \( \text{HBV} \) in prenatal women means that they would be treated as non-HBV cases and that their newborns would receive the less effective HBV vaccination protocol (4). Thus, mother-to-child transmission of \( \text{HBV} \) requires further investigation.

In conclusion, mother-to-teenager transmission of \( \text{HBV} \) may occur among those in a neonatal HBV vaccination program. As a consequence of the limitations of this small study, the exact role of maternal \( \text{HBV} \) remains unknown. A study of a large cohort of pregnant women with a longer follow-up period for both mothers and children would be ideal for investigating mother-to-child transmission of \( \text{HBV} \) and the effectiveness of current HBV vaccinations against both \( \text{HBV} \) and \( \text{HBV} \).

ACKNOWLEDGMENTS

This work was supported by grants from the Ministry of Science and Technology of the People’s Republic of China (2008ZX10002-012), the Shanghai Leading Academic Discipline Project (B118), and Zhejiang Medicines & Health Science and Technology Project (2009A203). We thank Shan Wei for her English editing.

REFERENCES


274 cvi.asm.org Clinical and Vaccine Immunology


